Pharmacological Treatment for Obesity in Adults: An Umbrella Review
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Objective: To synthesize the evidence from systematic reviews of clinical trials investigating the effectiveness of pharmacological therapies approved by the Australian Therapeutic Goods Administration and the US Food and Drug Administration for the management of obesity in adults. Data Sources: A 3-step literature search of the MEDLINE, EMBASE, CINAHL, and PubMed databases was conducted between March and May 2019. The key terms used were obesity, pharmacological therapy, antiobesity agent, antiobesity medication, weight loss, and systematic review. Study Selection and Data Extraction: Systematic reviews that evaluated the effectiveness of pharmacological therapies for the management of obesity in patients with a body mass index of or greater than 25 kg/m 2. Data Synthesis: Nine systematic reviews involving three pharmacotherapies, liraglutide, orlistat, and naltrexone-bupropion were identified. The results indicate that the pharmacotherapies reduced weight when compared with placebo. Orlistat was effective in significantly reducing fasting blood glucose, HbA1c, total cholesterol, triglycerides, and systolic and diastolic blood pressure. All reviews discussed the presence or risk of gastrointestinal adverse effects including diarrhea, vomiting, and nausea related to orlistat and liraglutide. Relevance to Patient Care and Clinical Practice: This umbrella review compares the efficacy and safety of antiobesity medications for reducing weight and a discussion on their weight loss and metabolic control to guide clinicians when prescribing medications for obesity. Conclusions: All pharmacological therapies included in this review are superior to placebo in reducing weight. Clinicians should consider patient comorbidities and risk of adverse events when recommending medications for weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Aromataris, E., Fernandez, R., Godfrey, C. M., Holly, C., Khalil, H., & Tungpunkom, P. (2015) · International Journal of Evidence-Based Healthcare · doi:10.1097/xeb.0000000000000055 · Cited by 2,587 · cited 2×
“Selected reviews were critically appraised by 2 independent reviewers (HL, HK) using the standardized JBI Critical Khalil et al 693 Appraisal Checklist for Systematic Reviews.16 The following quality thresholds were used: low quality (0% to 33% of criteria met), medium quality (34% to 66% of the criteria met), and hig…”
MethodSelf-citationFranz, M. J., VanWormer, J. J., Crain, A. L., Boucher, J. L., Histon, T., Caplan, W., Bowman, J. D., & Pronk, N. P. (2007) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2007.07.017 · Cited by 1,559
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
Khera, R., Murad, M. H., Chandar, A. K., Dulai, P. S., Wang, Z., Prokop, L. J., Loomba, R., Camilleri, M., & Singh, S. (2016) · JAMA · doi:10.1001/jama.2016.7602 · Cited by 865
Obesity Pathogenesis: An Endocrine Society Scientific Statement
Schwartz, M. W., Seeley, R. J., Zeltser, L. M., Drewnowski, A., Ravussin, E., Redman, L. M., & Leibel, R. L. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00111 · Cited by 727 · cited 1×
“Understood to be a result of the shifting metabolic processes brought about by obesity, evidence has observed in some obese individuals a “resetting” of their baseline set point weight.(5) When the application of comprehensive lifestyle interventions has failed to result in clinically significant and sustained weight…”
BackgroundLong-Acting Glucagon-Like Peptide 1 Receptor Agonists
Garber, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s231 · Cited by 350
Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
Madsbad, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12596 · Cited by 305
Potts, J. E., Gray, L. J., Brady, E. M., Khunti, K., Davies, M. J., & Bodicoat, D. H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126769 · Cited by 163 · cited 5×
“The critical appraisal tools/instruments used in the reviews were Cochrane,(14,19,20,24) Jadad scale,(15) Verhagen Delphi list,(22) and other “validated scales” (Table 1).(21,23,25) Weight change was the most frequently reported outcome.”
BackgroundMethodResultInfluentialPharmacological Therapies for Obesity
Kaplan, L. M. (2005) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2004.12.002 · Cited by 149
Cited by
Nadolsky, K., Addison, B., Agarwal, M., Almandoz, J. P., Bird, M. D., DeGeeter Chaplin, M., Garvey, W. T., & Kyle, T. K. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.03.272 · Cited by 86
McGowan, B., Ciudin, A., Baker, J. L., Busetto, L., Dicker, D., Frühbeck, G., Goossens, G. H., Monami, M., Sbraccia, P., Martinez-Tellez, B., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03765-w · Cited by 75
Nonsurgical weight loss interventions: a systematic review of systematic reviews and meta-analyses
Twells, L. K., Harris Walsh, K., Blackmore, A., Adey, T., Donnan, J., Peddle, J., Ryan, D., Farrell, A., Nguyen, H., Gao, Z., et al. (2021) · Obesity Reviews · doi:10.1111/obr.13320 · Cited by 33
Mohammadi, S., Rastmanesh, R., Jahangir, F., Amiri, Z., Djafarian, K., Mohsenpour, M. A., Hassanipour, S., & Ghaffarian-Bahraman, A. (2021) · BioMed Research International · doi:10.1155/2021/3502325 · Cited by 22
Metadata
- Authors
- Khalil, H., Ellwood, L., Lord, H., & Fernandez, R.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2020-01-20
- Volume
- 54
- Issue
- 7
- Pages
- 691-705
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W3001064076
- Cited by
- 44
- References
- 12
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological Treatment for Obesity in Adults: An Umbrella Review. https://app.cochat.ai/papers/10.1177/1060028019898912
- The paper
- Khalil, H., Ellwood, L., Lord, H., & Fernandez, R. (2020). Pharmacological Treatment for Obesity in Adults: An Umbrella Review. Annals of Pharmacotherapy. https://doi.org/10.1177/1060028019898912
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.